Daniel V. Ebner

SoftHybrid: A Hybrid Imputation Algorithm Optimised for Single-Cell Proteomics Data

SoftHybrid improves single-cell proteomics data imputation by jointly modeling missingness and protein abundance, outperforming existing methods at low input and matching them at the mini-bulk level.

Refined USP25/28 inhibitors with enhanced selectivity towards c-Myc driven squamous lung cancer cells

This study develops refined USP25/28 inhibitors that selectively target c-MYC driven squamous lung cancer cells with reduced off-target effects and toxicity.

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models

This study screens a large compound library across patient-derived GBM stem cells to identify effective drugs targeting tumor heterogeneity and presents validated hits for further exploration.

The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity

This paper shows that Dasatinib and glucocorticoids work together to kill tongue squamous cell carcinoma cells by reducing MET kinase activity and inducing cell cycle arrest and senescence.

Drug combinations targeting FAK and MEK overcomes tumour heterogeneity in glioblastoma

This study identifies a synergistic combination of FAK and MEK inhibitors that effectively targets glioblastoma heterogeneity and improves therapeutic outcomes.

A genome-wide CRISPR screen identifies regulators of beta cell function involved in type 2 diabetes risk

A genome-wide CRISPR screen in human pancreatic beta cells identifies 580 genes influencing insulin content, supporting 20 candidate type 2 diabetes effector transcripts.